Premium
Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate
Author(s) -
Drunen C.,
Meltzer E. O.,
Bachert C.,
Bousquet J.,
Fokkens W. J.
Publication year - 2005
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2005.00917.x
Subject(s) - mometasone furoate , medicine , nasal administration , allergy , nasal spray , clinical efficacy , dermatology , corticosteroid , pharmacology , immunology
Mometasone furoate nasal spray (MFNS; Nasonex ® , Schering‐Plough Corporation, Kenilworth, NJ, USA) is an effective and well‐tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.